Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | ||
| Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rozlytrek | entrectinib | Extracranial solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rukobia | fostemsavir | Human immunodeficiency virus type 1 (HIV-1) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
| Rybelsus | semaglutide | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rybrevant | amivantamab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
| Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete |
Last Updated : May 11, 2024